MedPath

Effect of Insulin Glulisin on postprandial plasma glucose levels in obese subjectts with type 2 diabetes after a standard meal in comparison to Insulin Lispro

Conditions
Obese subjects with type 2 diabetes mellitus
Registration Number
EUCTR2005-005914-18-DE
Lead Sponsor
Diabetes-Centre Quakenbrueck
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
30
Inclusion Criteria

Type 2 diabetic subjects
Age: > 30, < 80 years
Insulintherapy > 12 months
BMI: > 28, < 35 kg/m²
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Pregnancy
Nursing
Medication known to influence insulin sensitivity
Alcohol abuse
Drug abuse
Psychiatric illness

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Area under the curve (AUC) plasma glucose 0-1 h;Secondary Objective: AUC plasma glucose 0-4 h (end)<br>Difference plasma glucose at 1 h postprandially<br>AUC plasma insulin 0-1 h<br>AUC plasma insulin 0-4 h (end);Primary end point(s): Area under the curve (AUC) plasma glucose 0-1 h
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath